Hot Flushes | Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms
Hot Flushes research study
What is the primary objective of this study?
The purpose of this study is to test whether a oral micronized progesterone reduces the Vasomotor Symptom Score comprised of the number and severity of hot flushes and night sweats in perimenopausal women. Oral micronized progesterone is molecularly identical to human progesterone, a steroid hormone. It is sold by prescription for use to prevent endometrial cancer in women taking estrogen in menopause. This research study will test whether progesterone reduces perimenopausal hot flushes and night sweats. It will also test whether progesterone improves sleep disturbances and anxiety.
Who is eligible to participate?
Inclusion Criteria: 1. Between 35-58 years of age 2. At least 4 vasomotor symptoms (VMS) per day, on average, for at least 2/4 weeks or at least 56 over a four-week period. In addition, women should report having VMS of moderate or severe rather than mild intensity. Women reporting fewer VMS than this, but who report night sweats that awaken them from sleep on two or more nights per week will also be included. 3. Perimenopausal status either based on irregularity of menstrual periods, or by onset of new perimenopausal symptoms in women with regular periods. 4. At least one menstrual period within 12 months of study enrollment 5. Ability and willingness to complete the Daily Perimenopause Hot Flush Calendar recording instrument. 6. Ability to understand, speak, read and write English. 7. Women who are at high risk for breast cancer (ie first degree relative with breast cancer, known/suspected history of breast cancer) will be required to have a normal mammogram and clinical breast examination within 12 months of study enrollment. Exclusion Criteria: 1. VMS without perimenopausal etiology. 2. Women who have had a hysterectomy and/or ovariectomy. 3. Peanut allergy (because peanut oil is used in the progesterone formulation.) 4. Current or recent (within the last 6-mos.) use of hormonal therapies (estrogen, progesterone, hormonal contraceptives, hormonal fertility treatments), or plans to initiate use during the study period. Two exceptions: women using progestin-releasing intrauterine device (IUD) will not be excluded as it is felt that level of hormone released will not have an effect on VMS and women taking very low-dose transdermal progesterone therapies who have VMS and meet inclusion criteria will be considered on a case-by-case basis. If enrolled, they will be required to continue and document use of this very low-dose hormone therapy throughout the entire trial. 5. Planned pregnancy or fertility treatment during the study period. 6. Women who are breastfeeding. 7. Participants with a score greater or equal to 15 on the Personal Health Questionnaire (PHQ-9) will be assessed on a case-by-case basis. Women assessed as needing further investigation and/or treatment for depression will be excluded.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Oral micronized progesterone300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
Drug:placeboplacebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
oral micronized progesteroneOral micronized progesterone is Prometrium 300 mg at bedtime daily
Active, not recruiting
Start Date: October 2011
Completed Date: June 2017
Phase: Phase 3
Primary Outcome: Vasomotor Symptoms (VMS)/ VMS Score
Secondary Outcome: Frequency of VMS
Study sponsors, principal investigator, and references
Principal Investigator: Jerilynn C Prior, MD FRCPC
Lead Sponsor: University of British Columbia
Prior JC, Hitchcock, CL. Progesterone for Vasomotor Symptoms: A 12-week Randomized, Masked Placebo-controlled Trial in Healthy, Normal-Weight Women 1-10 Years Since Final Menstrual Flow (Abstract). Endocrine Reviews 31(3): S51, 2010.